TCRs recognizing MHC-presented peptides derived from non-mutated tumor antigens, such as cancer testis or tissue-specific antigens that are found in many tumors of the same type, could be used to treat larger patient cohorts. This evidence concerns the gene HLA-C and neoplasm.